Boston Scientific Corporation (NYSE: BSX) is back in the spotlight on Tuesday, December 16, 2025, as the stock trades in the low-$90s—well below its September highs—while Wall Street’s broader view remains notably upbeat on the medical-device leader’s growth outlook.
As of the latest available market data, BSX traded around $92.23 on Dec. 16, with an intraday range of roughly $90.44 to $92.77. That places the stock about 16% below its 52‑week high of $109.50 and roughly 7% above its 52‑week low of $85.98, highlighting how sharply sentiment has cooled since the late-summer peak even as fundamentals have stayed resilient.
What changed today? The short version: a fresh price-target reset from Baird, ongoing institutional positioning disclosures, and continued debate around whether the recent pullback is a normal “digesting gains” phase—or a warning sign that valuation and expectations had simply run too hot.
BSX stock today: where the shares stand on Dec. 16
Boston Scientific shares were indicated around $92 during Tuesday’s session, after a multi-week pullback that has dragged the stock below key moving averages tracked by many technicians. MarketBeat data, for example, shows BSX with a 50‑day moving average near $98.76 and a 200‑day moving average near $101.51, putting the stock below both—a classic “risk-off” technical setup even when the underlying business remains strong. MarketBeat
Market context matters too. A Reuters market update dated Dec. 16, 2025 described major U.S. indexes as roughly flat, with healthcare weakness offsetting strength in technology in volatile trading. That kind of sector rotation can amplify day-to-day pressure on large-cap healthcare names like BSX, particularly after a strong run earlier in the year.
What’s new on Dec. 16: Baird trims its target, but keeps a bullish rating
One of the most directly “stock-moving” updates tied to today’s date is a new analyst note headline:
- Baird adjusted its price target on Boston Scientific to $118 from $132 and maintained an Outperform rating, according to MT Newswires coverage published early Tuesday.
Because the full text of that note is not broadly accessible in public view, the reasoning behind the target cut isn’t fully detailed in open sources. Still, the headline itself is meaningful: it implies Baird remains constructive on the company’s competitive positioning and earnings power (rating unchanged) while dialing back valuation assumptions or near-term upside expectations (target reduced).
Institutional and insider activity in focus: fresh filings hit the tape
Beyond analyst notes, Dec. 16 also brings a familiar kind of “slow-burn” stock news: institutional ownership filings. Two MarketBeat items published today point to incremental positioning:
- Grove Bank & Trust reported it grew its BSX position sharply in the third quarter (per its 13F filing), and MarketBeat also notes institutional investors own a large share of BSX overall.
- B. Riley Wealth Advisors Inc. disclosed a new position in Boston Scientific shares (also based on SEC disclosure reporting).
These filings rarely change the long-term story by themselves, but they do reinforce a key point: BSX remains institutionally owned at a high level—MarketBeat puts institutional ownership at about 89%.
Investors also continue to watch insider activity. MarketBeat’s Dec. 16 snapshot references notable insider sales in recent weeks, including sales by senior executives and an estimate of insider selling over the last 90 days (with insider ownership still small overall).
Analyst forecasts for Boston Scientific stock: where “consensus” lands (and why it varies)
Despite the pullback and today’s price-target cut headline, the broader analyst picture remains strikingly positive.
Different data providers show slightly different counts and averages (because they pull from different analyst universes and update schedules), but the theme is consistent: most analysts remain in Buy territory, with average targets in the mid‑$120s and highs near $140.
1) TipRanks (12-month targets)
TipRanks shows an average price target of $127.15, with a high forecast of $140 and a low forecast of $113, and a consensus rating of Strong Buy based on its tracked analyst set.
2) Investing.com (consensus snapshot)
Investing.com’s consensus page shows an overall “Strong Buy” stance with 32 Buy, 2 Hold, 0 Sell, and an average 12-month price target around $126.48, with a range from $99 to $140. Investing.com
3) MarketScreener (consensus + target spread)
MarketScreener reports a mean consensus of “BUY,” with an average target price around $126.05, a high target of $140, and a low target of $99, based on a stated analyst count (shown as 34 on its page). MarketScreener
4) MarketBeat (average target)
MarketBeat shows BSX with an average target price of $125.15, a high of $140, and a low of $108, and characterizes the overall rating as “Buy.” MarketBeat+1
How to read this: Even after a meaningful slide from the highs, the Street’s “center of gravity” still points well above the current price—roughly 35%–37% implied upside depending on the dataset you use. MarketBeat+3TipRanks+3Investing.com+3
The fundamental backdrop: strong recent execution is still the bull case
The reason BSX still commands premium enthusiasm from analysts is rooted in recent financial performance and product-driven growth, particularly in cardiovascular markets.
Q3 2025: beat-and-raise momentum
In its third-quarter 2025 results, Boston Scientific reported adjusted EPS of $0.75 on revenue of about $5.07 billion, topping consensus expectations cited by Reuters. The company also reported net sales of $5.065 billion with strong year-over-year growth in its formal earnings release materials.
Reuters also reported that Boston Scientific raised its 2025 adjusted EPS outlook to $3.02–$3.04 and guided Q4 EPS to 77–79 cents. MarketBeat’s overview similarly lists FY2025 EPS guidance of $3.02–$3.04 and Q4 EPS guidance of $0.77–$0.79.
Product engines investors keep naming
Coverage of that Q3 report emphasized strength in key franchises. Investor’s Business Daily noted, for example, Watchman sales growth and a major surge in electrophysiology tools, helping power the quarter.
This mix—category leadership plus repeatable procedure volume—helps explain why analysts often treat BSX as a “compounder” even when the stock temporarily deflates.
Technical and sentiment snapshot: the pullback is real (and widely visible)
From a “tape reading” standpoint, the stock’s decline since September is hard to ignore:
- MarketWatch’s market data coverage earlier in December described BSX as extending a losing streak and noted the stock remained meaningfully below its $109.50 52-week high set in early September.
- On Dec. 16, MarketScreener’s snapshot also shows BSX hovering around $92.5 with a modest negative move over the last five sessions.
Meanwhile, some growth-oriented commentary continues to point to earnings estimate revisions as a supportive factor. A widely circulated summary of Zacks research (via FINVIZ) highlights upward estimate revisions and frames BSX as a growth-style pick—useful context for why buy-side interest often returns quickly on weakness.
What investors are weighing now:
- Is BSX’s move below widely watched moving averages simply a normal consolidation after a huge 2024–2025 run?
- Or is it the market starting to enforce a stricter valuation discipline on medtech leaders, especially into year-end rebalancing?
Key dates and catalysts to watch next
Next earnings: early February 2026 (estimates vary slightly)
Several tracking services point to early February 2026 as the next reporting window for Boston Scientific’s Q4/FY2025 update:
- MarketBeat says BSX has not confirmed the next earnings date, but estimates February 4, 2026 based on historical timing.
- TipRanks lists Feb. 4, 2026 (before open) and shows a consensus EPS forecast of $0.78 for the quarter.
- Nasdaq similarly lists an estimated earnings date of 02/04/2026 (algorithmic/estimated).
Corporate calendar visibility
Boston Scientific’s own investor relations events page states that, as of now, there are no upcoming events scheduled on its calendar (separate from earnings).
Risks still on the dashboard: regulatory and policy headlines can matter fast
Even for high-quality medtech operators, downside risk can arrive through external headlines. Investors have watched several themes during the past year:
- Tariffs and policy costs: Reuters reported Boston Scientific projected a $100 million tariff impact for the year (lower than a previously cited $200 million estimate), illustrating how policy variables can swing near-term modeling.
- Regulatory actions and product decisions: Reuters reported earlier in 2025 that Boston Scientific discontinued sales of certain aortic valve products in the EU and would not seek U.S. approval due to increased clinical/regulatory requirements.
- Device safety communications: The Associated Press reported in 2025 on FDA safety alerts tied to two Boston Scientific heart-device categories, which the market sometimes reacts to quickly even when the business impact is manageable over time.
None of these automatically changes the long-term thesis—but they help explain why even strong operators can see abrupt valuation resets.
Bottom line: BSX enters year-end with a “bullish Street, cautious chart” setup
On Dec. 16, 2025, Boston Scientific stock is presenting investors with a classic tension:
- Fundamentals and analyst sentiment remain broadly supportive, with consensus targets clustered around $125–$127 and highs near $140.
- Near-term price action has weakened materially since the September peak, and a notable new headline today is Baird’s price-target reduction (even while maintaining an Outperform view).
For investors, the next major “prove it” moment is likely the Q4/FY2025 earnings update in early February 2026, when the market will test whether Boston Scientific can keep delivering enough growth to justify premium expectations—and whether the recent pullback has created opportunity or simply reset the trading range. MarketBeat+2TipRanks+2
